We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Phase II Study of Single-Agent Rituximab in Previously Treated Multiple Myeloma Patients: Patients With CD20-Positive Bone Marrow Plasma Cells May Derive Benefit From Rituximab

Mar 1, 2001
Volume: 
15
Issue: 
3
  • Multiple Myeloma

The anti-CD20 chimeric monoclonal antibody rituximab (Rituxan)
has been successfully used in the treatment of many B-cell malignancies.
Clonotypic B cells circulating in multiple myeloma (MM) patients express CD20,
and it has been suggested that these cells may function as precursor cells.
Moreover, 20% of multiple myeloma patients express CD20 on their bone marrow
plasma cells (BMPC). We therefore undertook a phase II clinical study to
determine the activity of rituximab in MM patients. As part of this study, we
performed immunophenotyping in order to correlate CD20 expression on bone marrow
and peripheral blood mononuclear cells with response to rituximab therapy.

Nineteen MM patients (median age: 62 years; range: 36 to 88
years) who were previously treated (median prior therapies: 4; range: 1 to 6
therapies) received rituximab at 375 mg/m2 /wk for 4 weeks. Three months
following the start of treatment, patients were assessed for response; they
received a second course of therapy if they attained stable disease or had a
major response.

Six of 19 (32%) patients achieved either a partial response (n =
1) or had stable disease (n = 5), with a median time to treatment failure of 5.5
months (range: 3 to 21+ months). Interestingly, 5 of these 6 patients had
CD20-positive BMPC; CD20 status could not be determined for the bone marrow
tumor cells for one patient. Overall, rituximab therapy was well tolerated,
although one MM patient developed moderate hemoptysis, which was self-limiting,
after receiving one cycle of rituximab.

CONCLUSION: These studies suggest that certain MM patients, ie,
those with CD20-positive BMPC, may derive benefit from rituximab therapy.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Articles

  • Excess Mortality Risk Shows Myeloma Is Still ‘Incurable’
  • High BMI in Early Adulthood Increased Myeloma Risk
  • Ixazomib Triplet Combo Effective in R/R Myeloma
  • Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
  • Denosumab Approved for Skeletal-Related Events in Myeloma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.